Últimas noticias sobre Organon (NYSE:OGN) Bolsa

Organon

Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.

Organon & Co

Origin Protocol - United States dollar

OROGEN ROYALTIES INC by OROGEN ROYALTIES INC

Orogen Royalties Inc.

ORGANA TECHS GRP INC by Organa Technologies Group, Inc.

<a href="https://www.bloomberg.com/news/articles/2025-07-22/spacex-warns-investors-elon-musk-could-return-to-us-politics">https://www.bloomberg.com/news/articles/2025-07-22/spacex-warns-investors-elon-musk-could-return-to-us-politics</a>

News

General

TSLA

'SpaceX Warns Investors Elon Musk Could Return to US Politics'- Bloomberg

<a href="https://www.bloomberg.com/news/articles/2025-07-22/hershey-raising-prices-double-digits-due-to-high-cocoa-costs">https://www.bloomberg.com/news/articles/2025-07-22/hershey-raising-prices-double-digits-due-to-high-cocoa-costs</a>

'Hershey Raising Candy Prices by Double Digits on High Cocoa Costs'- Bloomberg

Barclays analyst Matt Miksic upgrades ZimVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZIMV#NASDAQ">ZIMV</a>) from Underweight to Equal-Weight and raises the price target from $9 to $19.

Upgrades

Price Target

Analyst Ratings

ZIMV

Barclays Upgrades ZimVie to Equal-Weight, Raises Price Target to $19

<a href="https://trumpstruth.org/statuses/32150">https://trumpstruth.org/statuses/32150</a>

PARA

President Trump Says Paramount, CBS, 60 Minutes Have Today Paid $16M Dollars In Settlement; We Anticipate Receiving $20M More From New Owners; Other Mainstream Media On Notice;

WIIM

Interpublic Group shares are trading higher after the company reported better-than-expected Q2 financial results and announced the launch of Agentic Systems for Commerce.

JP Morgan analyst Anupam Rama downgrades Replimune Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REPL#NASDAQ">REPL</a>) from Overweight to Neutral and lowers the price target from $19 to $9.

Downgrades

REPL

JP Morgan Downgrades Replimune Group to Neutral, Lowers Price Target to $9

Caris Life Sciences shares are trading higher after the company announced it will publish recent findings regarding tumor-infiltrating clonal hematopoiesis in the New England Journal of Medicine.

AstraZeneca plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) announced on Tuesday that it will invest $50 billion in the <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">United States by 2030</a>.
The investment will create new, highly skilled direct and indirect jobs nationwide, the company <a target="_blank" href="https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-plans-to-invest-50bn-dollars-in-the-us.html" rel="noreferrer noopener">said</a>.
The cornerstone of this landmark investment is a new multi-billion-dollar U.S. manufacturing facility that will produce drug substances for the company's weight management and metabolic portfolio, including oral GLP-1, baxdrostat, oral PCSK9, and combination small-molecule products.
The new centre will produce small molecules, peptides, and oligonucleotides.
This multi-billion dollar capital investment is in addition to the $3.5 billion announced in November 2024.
The drug substance facility, planned for the Commonwealth of Virginia, would be AstraZeneca's largest single manufacturing investment in the world. It will leverage AI, automation, and data analytics to optimize production.
<h2 class="wp-block-heading">What Does The Investment Include?</h2>
The $50 billion investment across R&amp;D and manufacturing footprint in the U.S. over the next five years also includes:
<ul class="wp-block-list">
<li>Expansion of R&amp;D facility in Gaithersburg, Maryland</li>
<li>R&amp;D centre in Kendall Square, Cambridge, Massachusetts</li>
<li>Manufacturing facilities for cell therapy in Rockville, Maryland and Tarzana, California</li>
<li>Manufacturing expansion in Mount Vernon, Indiana</li>
<li>Specialty manufacturing expansion in Coppell, Texas</li>
<li>New sites to supply clinical trials.</li>
</ul>
The company said collectively, these investments will help deliver AstraZeneca's <a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/38936595/astrazeneca-targets-ambitious-80b-in-total-revenue-by-2030-through-pipeline-expansion" rel="noreferrer noopener">ambition of reaching $80 billion</a> in Total Revenue by 2030, of which 50% would be generated in the U.S.
Howard Lutnick, U.S. Secretary of Commerce, said: "For decades Americans have been reliant on foreign supply of key pharmaceutical products. President Trump and our nation's new tariff policies are focused on ending this structural weakness. We are proud that AstraZeneca has made the decision to bring substantial pharmaceutical production to our shores."
<a target="_blank" href="https://www.benzinga.com/25/05/45234032/fda-expands-surprise-inspections-at-foreign-drug-and-food-facilities-targets-double-standards-in-overseas-manufacturing-oversight" rel="noreferrer noopener">Amid tariff uncertainty</a>, many drug companies are investing to boost production within the U.S. Most recently, Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) said that it plans to invest an additional $2 billion in its existing manufacturing footprint in North Carolina's Research&nbsp;<a target="_blank" href="https://www.benzinga.com/news/health-care/25/07/46529101/biogen-bets-big-on-2-billion-expansion-to-boost-us-drug-manufacturing" rel="noreferrer noopener">Triangle Park (RTP)</a>.
Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) doubled&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43982604/eli-lilly-doubles-capital-spending-on-us-drug-manufacturing-with-50-billion-target" rel="noreferrer noopener">domestic medicine production</a>.
Thermo Fisher Scientific Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) announced it would invest an additional $2 billion in the U.S. over&nbsp;<a target="_blank" href="https://www.benzinga.com/general/health-care/25/04/44995428/thermo-fisher-doubles-down-on-us-manufacturing-in-2b-expansion-plan" rel="noreferrer noopener">the next four years</a>.
Medtech firm&nbsp;Becton, Dickinson, and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) also announced its intention to invest&nbsp;$2.5 billion&nbsp;in U.S. manufacturing capacity&nbsp;<a target="_blank" href="https://www.benzinga.com/general/health-care/25/05/45140102/potential-tariff-bites-into-becton-dickinson-2025-profit-outlook-company-will-invest-2-5-billion-to-boost-us-manufacturing" rel="noreferrer noopener">over the next five years</a>.
Regeneron Pharmaceuticals, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) seeks to nearly double its manufacturing capacity through a new agreement with&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44931246/regeneron-partners-with-japan-based-fujifilm-to-bolster-us-manufacturing-capacity-via-3-billion-deal" rel="noreferrer noopener">FUJIFILM Diosynth Biotechnologies</a>. Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) unveiled a $23 billion investment plan to expand in the U.S.&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44761201/novartis-commits-23-billion-to-expand-us-manufacturing-over-five-years-despite-tariffs-uncertaint" rel="noreferrer noopener">over the next five years</a>.
Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) plans to invest more than&nbsp;<a target="_blank" href="https://www.benzinga.com/markets/equities/25/03/44433978/johnson-johnson-to-invest-55-billion-in-us-to-boost-manufacturing-drug-discovery" rel="noreferrer noopener">$55 billion in the U.S. over the next four years</a>. Roche Holdings AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) announced that it will invest $50 billion in the U.S. over&nbsp;<a target="_blank" href="https://www.benzinga.com/topic/pharmaceuticals" rel="noreferrer noopener">the next five years.</a>
Bristol-Myers Squibb &amp; Co.'s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Christopher Boerner, chair and chief executive officer,&nbsp;<a target="_blank" href="https://www.statnews.com/2025/05/05/bristol-myers-squibb-pharmaceutical-policy-us-trump-administration-innovation-tariffs/?tblci=GiCUX7wvU_AgmIIiQduNYr6JQuJQLy6SZJGvpyeZuCzyqiCN1VcoxvTN4f7-y-PqATDviEo" rel="noreferrer noopener">shared</a> plans to invest $40 billion in U.S. R&amp;D, technology, and manufacturing over the next five years. Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) announced it will invest at least&nbsp;$20 billion&nbsp;in&nbsp;the&nbsp;<a target="_blank" href="https://www.benzinga.com/25/05/45419235/sanofi-joins-other-big-pharma-to-navigate-potential-tariff-impact-with-at-least-20-billion-in-investments-through-2030" rel="noreferrer noopener">U.S.&nbsp;through 2030</a>. The bulk of the spending will go to R&amp;D and U.S. manufacturing.
Price Action: AZN stock is up 2.34% at $70.33 at the last check on Tuesday
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/07/46551856/pony-ai-stock-surges-as-autonomous-system-hits-key-milestone" target="_blank" rel="noreferrer noopener">Pony AI Stock Surges As Autonomous System Hits Key Milestone</a></li>
</ul>
Photo by JHVEPhoto via Shutterstock

Biotech

Large Cap

Health Care

Movers

BIIB

REGN

RHHBY

Trump Tariffs Forces AstraZeneca To Bring Substantial Pharmaceutical Production To US

Synovus shares are trading higher after a report suggesting the company is weighing a potential merger following takeover interest.

<a href="https://www.bloomberg.com/news/articles/2025-07-22/synovus-weighs-potential-merger-after-drawing-takeover-interest?srnd=homepage-americas">https://www.bloomberg.com/news/articles/2025-07-22/synovus-weighs-potential-merger-after-drawing-takeover-interest?srnd=homepage-americas</a>

'Synovus Weighs Potential Merger After Drawing Takeover Interest'- Bloomberg

Core Natural Resources shares are trading higher. B. Riley Securities maintained a Buy rating on the stock.

Warrior Met Coal shares are trading higher. B. Riley Securities maintained a Buy rating on the stock.

TIGR

UP Fintech Holdings shares are trading higher after Citigroup upgraded the stock from Neutral to Buy and raised its price target from $9.5 to $14.

CYRX

CryoPort shares are trading higher after Stephens & Co. assumed an Overweight rating on the stock and announced a price target of $13.

Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) on Tuesday agreed to acquire Vicebio Ltd, a privately held biotechnology company headquartered in London, U.K.
The acquisition brings an early-stage combination vaccine candidate for respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">both respiratory viruses</a>, and expands the capabilities in vaccine design and development with Vicebio&#8217;s &#8216;Molecular Clamp&#8217; technology.
The vaccine candidate complements Sanofi&#8217;s position in the respiratory vaccines space, where the company is present in flu and RSV prevention. It allows Sanofi to offer increased physician and patient choice in RSV and hMPV by adding a non-mRNA vaccine to its pipeline.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/fda/25/07/46423319/gsk-seeks-fda-nod-to-broaden-rsv-vaccine-for-younger-at-risk-adults" rel="noreferrer noopener">GSK Seeks FDA Nod To Broaden RSV Vaccine For Younger At-Risk Adults</a>
The acquisition also adds &#8216;Molecular Clamp,&#8217; a technology stabilizing viral proteins in their native shape, enabling the immune system to recognize and respond to them more effectively.
The approach enables quicker development of fully liquid combination vaccines stored at standard refrigeration temperatures (2–8°C), eliminating the need for freezing or freeze-drying, thereby simplifying manufacturing and distribution.
Furthermore, fully liquid vaccines can be made available in prefilled syringes, enhancing ease of use, safety, and operational efficiency across healthcare settings.&nbsp;
Under the terms of the agreement, Sanofi would <a target="_blank" href="https://www.sanofi.com/en/media-room/press-releases/2025/2025-07-22-05-30-00-3119150" rel="noreferrer noopener">acquire</a> all of Vicebio&#8217;s share capital for a total upfront payment of $1.15 billion, with potential milestone payments of up to $450 million based on development and regulatory achievements.
The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions, including receipt of regulatory approvals. The acquisition will not have a significant impact on Sanofi&#8217;s financial guidance for 2025.
Vicebio&#8217;s pipeline includes VXB-241, a bivalent vaccine candidate targeting RSV and hMPV, currently in an exploratory phase 1 study in older adults, and VXB-251, a preclinical trivalent vaccine candidate targeting RSV, hMPV, and parainfluenza virus Type 3 (PIV3).
This acquisition reinforces Sanofi&#8217;s commitment to innovation in respiratory vaccines. In June, Sanofi said it is shipping Beyfortus (nirsevimab) starting in early Q3 to ensure broad availability well ahead of the 2025-2026 RSV season, which typically starts in November and <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/45839621/beyfortus-output-tripled-as-sanofi-astrazeneca-scale-up-for-rsv-season" rel="noreferrer noopener">runs through March</a>.
Sanofi, in collaboration with its partner AstraZeneca plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), has tripled production capacity and doubled the number of manufacturing sites since the launch of Beyfortus in 2023.
This acquisition follows another significant move by Sanofi in June 2025, when it agreed to acquire Blueprint Medicines Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) for <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/45719179/sanofi-expands-rare-immunology-portfolio-with-blueprint-buyout" rel="noreferrer noopener">approximately $9.1 billion</a>.
That acquisition included Ayvakit/Ayvakyt (avapritinib), a rare immunology disease medicine approved in the U.S. and the EU, along with a promising advanced and early-stage immunology pipeline.
Price Action: SNY stock is trading higher by 1.42% to $48.61 at last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46551879/ai-bubble-is-more-unhinged-than-dot-com-a-chilling-warning-from-the-inside" target="_blank" rel="noreferrer noopener">AI Bubble Is More Unhinged Than Dot-Com—A Chilling Warning From The Inside</a></li>
</ul>
Photo by HJBC via Shutterstock

BPMC

Sanofi Expands Respiratory Vaccine Portfolio With UK Biotech Buy

PNC Financial Services Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNC#NYSE">PNC</a>) unit PNC Bank and Coinbase Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) announced on Tuesday a strategic alliance to broaden secure cryptocurrency offerings and extend banking services for<a href="https://www.benzinga.com/pressreleases/25/07/n46545762/pnc-bank-coinbase-announce-strategic-partnership-to-advance-digital-asset-solutions-and-expand-ban" target="_blank" rel="noreferrer noopener"> retail and institutional clients.</a>
Under the agreement, PNC Bank will integrate Coinbase&#8217;s Crypto‑as‑a‑Service platform to enable customers to buy, hold and sell digital assets, while also delivering tailored banking solutions to Coinbase itself.
The partnership combines PNC&#8217;s longstanding client service expertise with Coinbase&#8217;s institutional‑grade infrastructure, giving users seamless, secure access to cryptocurrency markets.
Also Read:<a target="_blank" href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46543876/jamie-dimon-once-called-bitcoin-a-fraud-now-jpmorgan-might-lend-against-it" rel="noreferrer noopener"> Jamie Dimon Once Called Bitcoin A &#8216;Fraud&#8217;—Now JPMorgan Might Lend Against It</a>
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, PNC stock has gained over 11% in the past year. Investors can gain exposure to the stock via&nbsp;iShares U.S. Regional Banks ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IAT#NYSE">IAT</a>).
As part of the deal, PNC Bank will provide deposit accounts, treasury management and other core financial products to support Coinbase&#8217;s growth and strengthen system resiliency.
By uniting PNC&#8217;s banking network with Coinbase&#8217;s digital asset capabilities, the collaboration aims to foster a more resilient, innovative financial ecosystem.
&#8220;Partnering with Coinbase accelerates our ability to bring innovative, crypto financial solutions to our clients,&#8221; said William S. Demchak, PNC chairman and CEO.
Brett Tejpaul, head of&nbsp;Coinbase&nbsp;Institutional, said, &#8220;PNC is a market leader in delivering best-in-class products for their clients.&#8221;
&#8220;We&#8217;re thrilled to support their entry into the digital asset market with our leading&nbsp;Crypto&nbsp;as a Service platform, which provides PNC with a powerful set of tools to develop a scalable, high-growth business, built on a foundation of uncompromising security,&#8221; Tejpaul added.
COIN stock has gained over 51% in the past year. Investors can gain exposure to the stock via First Trust SkyBridge Crypto Industry and Digital Economy ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRPT#NYSE">CRPT</a>).
PNC, COIN Price Actions: PNC Financial Services Group shares are trading higher by 1.15% to $198.31; Coinbase was down 1.75% at $406.47 at publication on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/25/07/46535957/ethereum-roars-to-3-800-whats-driving-the-surge" target="_blank" rel="noreferrer noopener">Ethereum Roars To $3,800: What's Driving The Surge?</a></li>
</ul>
Photo: PNC, courtesy PNC; Coinbase via Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

Fintech news covering the emerging Financial Technology services sector

Fintech

Markets

COIN

CRPT

iShares Dow Jones US Regional Banks Index Fund

PNC, Coinbase Partnership Aims To Revolutionize Crypto Banking Infrastructure

Needham analyst Quinn Bolton maintains NXP Semiconductors (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>) with a Buy and raises the price target from $225 to $250.

NXPI

Needham Maintains Buy on NXP Semiconductors, Raises Price Target to $250

Jefferies analyst Roger Song maintains Replimune Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REPL#NASDAQ">REPL</a>) with a Buy and lowers the price target from $31 to $6.

Jefferies Maintains Buy on Replimune Group, Lowers Price Target to $6

Danaher Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>)&nbsp;on Tuesday reported second-quarter 2025 sales of $5.94 billion, up 3.5% year-over-year, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $5.84 billion</a>.&nbsp;
The life science giant reported adjusted earnings of $1.80 per share, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/n46538741/danaher-reports-second-quarter-2025-results" rel="noreferrer noopener">beating the consensus of $1.64</a>.
Non-GAAP core revenue increased 1.5% year over year, compared to the expectations of a growth in <a target="_blank" href="https://www.benzinga.com/general/health-care/25/04/44921061/danaher-beats-q1-expectations-signals-caution-ahead-in-unusual-times" rel="noreferrer noopener">low single digits</a> year over year.
Operating cash flow was $1.3 billion, and non-GAAP&nbsp;free cash flow was $1.1 billion.
Danaher's second-quarter adjusted operating profit margin of 27.3% exceeded expectations of around 25.5%.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/04/44966205/analyst-sees-opportunity-in-danaher-stock-as-sentiment-improves" rel="noreferrer noopener">Analyst Sees Opportunity In Danaher Stock As Sentiment Improves</a>
Biotechnology&nbsp;<a target="_blank" href="https://filecache.investorroom.com/mr5ir_danaher/934/Q2%202025%20Danaher%20Earnings%20Presentation.pdf" rel="noreferrer noopener">sales</a> increased to $1.85 billion compared to $1.71 billion a year ago, with core growth of 6%.
Sales in the Life Sciences segment remained flat at $1.78 billion, and diagnostic sales increased from $2.26 billion to $2.31 billion.
The company said, "DBS-driven execution, paired with another quarter of +HSD growth in Bioprocessing and disciplined cost management, enabled us to exceed our Q2 adjusted EPS and cash flow expectations."
<h2 class="wp-block-heading">Guidance</h2>
Danaher raised fiscal 2025 adjusted earnings guidance from $7.60-$7.75 per share to $7.70-$7.80, compared to the consensus of $7.70. The company cites good traction on cost initiatives.
Danaher&nbsp;<a target="_blank" href="https://investors.danaher.com/image/Q1+2025+Earnings+Supplement.pdf" rel="noreferrer noopener">reaffirms</a> that in fiscal year 2025, non-GAAP core revenue will grow by approximately 3% year over year.
Cepheid 2025 respiratory revenues will be around&nbsp;$1.7 billion.
The company expects an adjusted operating profit margin of around 25.5%.
Biotechnology core revenue growth is expected to be approximately 6% for the third quarter of 2025 and around 7% for the fiscal year 2025.
Life sciences core revenue will remain flat for the third quarter and fiscal year 2025.
Diagnostics sales are expected to increase in the low single digits in the third quarter and flat to low single digits in fiscal year 2025.
<h2 class="wp-block-heading">Management update</h2>
Danaher announced Matthew Gugino, currently group CFO of Life Sciences Innovations Group and VP of Financial Planning &amp; Analysis, will succeed Matthew McGrew as Danaher's CFO, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/n46538769/danaher-announces-transition-plan-for-chief-financial-officer" rel="noreferrer noopener">effective February 28, 2026</a>.
<h2 class="wp-block-heading">Analyst Opinion</h2>
William Blair writes that the macro backdrop for life science tools and bioprocessing companies was anything but sanguine in the second quarter, with escalating concerns surrounding the funding environment, tariffs, MFN, and whether these uncertainties resulted in a slowdown in the overall demand environment."
Danaher's results suggest that was not the case, at least in the second quarter, particularly within bioprocessing. Analyst Matt Larew maintains<a target="_blank" href="https://www.benzinga.com/quote/DHR/analyst-ratings" rel="noreferrer noopener"> the Outperform rating</a>.
Price Action: DHR stock is trading 0.68% higher at $189.34 at the last check on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/07/46548132/marlboro-parent-philip-morris-internationals-smoke-free-segment-powers-q2-gains" target="_blank" rel="noreferrer noopener">Marlboro Parent Philip Morris International's Smoke-Free Segment Powers Q2 Gains</a></li>
</ul>
Photo via Shutterstock

Analyst Color

Earnings

Guidance

Danaher Lifts 2025 Earnings Outlook Amid Biotech Growth, Cost Discipline

Interpublic Group Launches Agentic Systems For Commerce To Help Brands Manage Scaled And Complex Commerce Ecosystem With Automation And AI

Legal

Press Releases

DEADLINE TOMORROW: Berger Montague Advises Organon & Co. (NYSE: OGN) Investors to Inquire About a Securities Fraud Class Action by July 22, 2025

Deadline Soon: Organon & Co. (OGN) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

OGN Investors Have Opportunity to Lead Organon & Co. Securities Fraud Lawsuit with the Schall Law Firm

OGN Shareholders Have the Right to Lead the Organon & Co. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - OGN

The Gross Law Firm Notifies Organon & Co. Investors of a Class Action Lawsuit and Upcoming Deadline – OGN

Organon To Report Second Quarter 2025 Results and Host Conference Call on August 5, 2025

ORGANON FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Organon & Co. (OGN) Investors of the July 22nd Deadline and Urges Them to Inquire About Their Rights in Class Action Lawsuit

Organon & Co. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 22, 2025 to Discuss Your Rights - OGN

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Organon & Co. of Class Action Lawsuit and Upcoming Deadlines - OGN

Comments

Organon

Noticias

Últimas noticias sobre Organon (NYSE:OGN) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL